A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Apolipoprotein C-III (apoC-III) inhibits triglyceride hydrolysis and has been implicated in coronary artery disease. Through a genome-wide association study, we have found that about 5% of the Lancaster Amish are heterozygous carriers of a null mutation (R19X) in the gene encoding apoC-III ( APOC3 ) and, as a result, express half the amount of apoC-III present in noncarriers. Mutation carriers compared with noncarriers had lower fasting and postprandial serum triglycerides, higher levels of HDL-cholesterol and lower levels of LDL-cholesterol. Subclinical atherosclerosis, as measured by coronary artery calcification, was less common in carriers than noncarriers, which suggests that lifelong deficiency of apoC-III has a cardioprotective effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss-of-function variants of APOC3 that result in reduced synthesis of the protein are associated with absent or low circulating apoCIII levels, increased efficiency of TG removal from TRL, and lower plasma TG levels,59,60”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [60]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, rare heterozygous LOF variants in APOC3 encoding apo C-III are associated with ∼50% reduced TG levels and significantly increased clearance of very-low-density lipoprotein (VLDL).8,9”
From Clinical review on triglycerides (2020) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and is a genetically validated target to reduce ASCVD risk.8–10,64–66”
From Clinical review on triglycerides (2020) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Founder populations (such as those from Finland and Iceland) have provided multiple examples of otherwise rare risk alleles driven to higher frequency locally through drift and/or selection49–52.”
From A brief history of human disease genetics (2020) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apolipoprotein C-III is a central regulator of triglyceride metabolism that limits the clearance of triglyceride-rich lipoproteins through inhibition of lipoprotein lipase and hepatic uptake of triglyceride-rich lipoprotein remnants. 6-8”
From Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia (2025) · cites this paper as [7]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups
Detrano, R., Guerci, A. D., Carr, J. J., Bild, D. E., Burke, G., Folsom, A. R., Liu, K., Shea, S., Szklo, M., Bluemke, D. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa072100 · Cited by 2,989
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Goldstein, J. L., Schrott, H. G., Hazzard, W. R., Bierman, E. L., & Motulsky, A. G. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107332 · Cited by 1,443
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Cited by
Items 101–200 of 682
The Role of Lipids and Lipoproteins in Atherosclerosis
Linton, M. F., Yancey, P. G., Davies, S. S., Jerome, W. G., Linton, E. F., Song, W., Doran, A. C., & Vickers, K. C. (2015) · Europe PMC (PubMed Central) · Cited by 153
Qin, W., Sundaram, M., Wang, Y., Zhou, H., Zhong, S., Chang, C.-C., Manhas, S., Yao, E. F., Parks, R. J., McFie, P. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.203679 · Cited by 107
Coronary Artery Disease Genetics Enlightened by Genome-Wide Association Studies
Kessler, T., & Schunkert, H. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.04.001 · Cited by 123
Jensen, M. K., Aroner, S. A., Mukamal, K. J., Furtado, J. D., Post, W. S., Tsai, M. Y., Tjønneland, A., Polak, J. F., Rimm, E. B., Overvad, K., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.031276 · Cited by 105
“Use of blood pressure-lowering drugs, n (%) 2136 (38) 192 (11)”
Self-citationIncreased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes
Kanter, J. E., Shao, B., Kramer, F., Barnhart, S., Shimizu-Albergine, M., Vaisar, T., Graham, M. J., Crooke, R. M., Manuel, C. R., Haeusler, R. A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127308 · Cited by 105
Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
Taskinen, M.-R., Packard, C. J., & Borén, J. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0791-9 · Cited by 103
Personalized medicine in diabetes mellitus: current opportunities and future prospects
Kleinberger, J. W., & Pollin, T. I. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12757 · Cited by 124
Self-citationHolleboom, A. G., Karlsson, H., Lin, R.-S., Beres, T. M., Sierts, J. A., Herman, D. S., Stroes, E. S. G., Aerts, J. M., Kastelein, J. J. P., Motazacker, M. M., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.11.005 · Cited by 101
“The current postprandial lipid data are moreover remarkably similar to those reported by Pollin, who studied the effects of an APOC3 non-sense mutation on postprandial lipid levels (Pollin et al., 2008).”
ResultApolipoprotein C-III in triglyceride-rich lipoprotein metabolism
Ramms, B., & Gordts, P. L. S. M. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000502 · Cited by 101
Antisense oligonucleotides for the treatment of dyslipidaemia
Visser, M. E., Witztum, J. L., Stroes, E. S. G., & Kastelein, J. J. P. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs084 · Cited by 103
“Genetic studies in humans have associated lower levels of apoC-III with lower triglyceride levels possibly with improved health and extended longevity.(37) In animal models, the administration of apoC-III ASOs resulted in reductions in plasma triglyceride levels of 40–60%.”
BackgroundApolipoprotein C-III and hepatic triglyceride-rich lipoprotein production
Yao, Z., & Wang, Y. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328352dc70 · Cited by 100
“On the contrary, loss-of-function mutations within the human APOC3 gene have been associated with hypotriglyceridemia [5], hyperalphalipoproteinemia [6], and cardioprotective lipid/lipoprotein profiles in the Old Order Amish population [7].”
BackgroundEffects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism
Reyes-Soffer, G., Sztalryd, C., Horenstein, R. B., Holleran, S., Matveyenko, A., Thomas, T., Nandakumar, R., Ngai, C., Karmally, W., Ginsberg, H. N., et al. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.311476 · Cited by 97
Self-citationBartlett, J., Predazzi, I. M., Williams, S. M., Bush, W. S., Kim, Y., Havas, S., Toth, P. P., Fazio, S., & Miller, M. (2016) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.002436 · Cited by 96
“Men 135 (34) 83 (15) 136 (21) 86 (12) 145 (31) 86 (11) 137 (25) 86 (13) 152 (28)”
Self-citationShuldiner, A. R., PALMER, K. M., Pakyz, R. E., Alestock, T. D., Maloney, K. A., O'Neill, C., Bhatty, S., Schub, J., Overby, C. L., Horenstein, R. B., et al. (2014) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31396 · Cited by 99
Self-citationThe Importance of Lipoprotein Lipase Regulation in Atherosclerosis
Kumari, A., Kristensen, K. K., Ploug, M., & Winther, A.-M. L. (2021) · Biomedicines · doi:10.3390/biomedicines9070782 · Cited by 115
“Further consolidating this association, life-long deficiency of ApoC-III has a cardioprotective and anti-atherosclerotic profile [130], while increased ApoC-III level is associated with a higher risk of CHD [131].”
BackgroundKinetics of plasma triglycerides in abdominal obesity
Björnson, E., Adiels, M., Taskinen, M., & Borén, J. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000375 · Cited by 105
Tachmazidou, I., Dedoussis, G., Southam, L., Farmaki, A.-E., Ritchie, G. R. S., Xifara, D. K., Matchan, A., Hatzikotoulas, K., Rayner, N. W., Chen, Y., et al. (2013) · Nature Communications · doi:10.1038/ncomms3872 · Cited by 96
Self-citationSoutham, L., Gilly, A., Süveges, D., Farmaki, A.-E., Schwartzentruber, J., Tachmazidou, I., Matchan, A., Rayner, N. W., Tsafantakis, E., Karaleftheri, M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15606 · Cited by 98
Using population isolates in genetic association studies
Hatzikotoulas, K., Gilly, A., & Zeggini, E. (2014) · Briefings in Functional Genomics · doi:10.1093/bfgp/elu022 · Cited by 94
“This study also demonstrated that associations discovered in population isolates can be generalizable, as the same variant (R19X) had previously been discovered in the Amish founder population [71].”
ResultVery low-depth whole-genome sequencing in complex trait association studies
Gilly, A., Southam, L., Suveges, D., Kuchenbaecker, K., Moore, R., Melloni, G. E. M., Hatzikotoulas, K., Farmaki, A.-E., Ritchie, G., Schwartzentruber, J., et al. (2019) · Bioinformatics · doi:10.1093/bioinformatics/bty1032 · Cited by 93
Genetics of human longevity within an eco-evolutionary nature-nurture framework
Giuliani, C., Garagnani, P., & Franceschi, C. (2018) · Circulation Research · doi:10.1161/circresaha.118.312562 · Cited by 92
Is a High HDL-Cholesterol Level Always Beneficial?
Franczyk, B., Rysz, J., Ławiński, J., Rysz-Górzyńska, M., & Gluba-Brzózka, A. (2021) · Biomedicines · doi:10.3390/biomedicines9091083 · Cited by 105
TM6SF2 rs58542926 impacts lipid processing in liver and small intestine
O'Hare, E. A., Yang, R., Yerges‐Armstrong, L. M., Sreenivasan, U., McFarland, R., Leitch, C. C., Wilson, M. H., Narina, S., Gorden, A., Ryan, K. A., et al. (2017) · Hepatology · doi:10.1002/hep.29021 · Cited by 92
“A high-fat feeding intervention was performed in the ACDRP cohort to evaluate the effect of E167K on fasting and postchallenge lipid traits.((20)) Institutional review board approval was obtained from the Geisinger Clinic and University of Maryland, and all subjects provided written informed consent.”
MethodSelf-citationHypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding
Sniderman, A. D., Couture, P., Martin, S. S., DeGraaf, J., Lawler, P. R., Cromwell, W. C., Wilkins, J. T., & Thanassoulis, G. (2018) · Journal of Lipid Research · doi:10.1194/jlr.r082271 · Cited by 92
“(55) that a null mutation of apoCIII in Old Order Amish individuals was associated with lower levels of LDL-C, lower levels of fasting and postprandial triglycerides, higher HDL-C, and a lower prevalence of coronary calcification in carriers compared with noncarriers.”
BackgroundTriglyceride-rich lipoproteins and remnants: targets for therapy?
Dallinga-Thie, G. M., Kroon, J., Borén, J., & Chapman, M. J. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0745-6 · Cited by 90
Taskinen, M.-R., & Borén, J. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0614-1 · Cited by 90
Novel functional APOB mutations outside LDL-binding region causing familial hypercholesterolaemia
Alves, A. C., Etxebarria, A., Soutar, A. K., Martín, C., & Bourbon, M. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt573 · Cited by 103
“Arg19X (50,51), were amplified and sequenced as described before (4,20).”
MethodMazur, M. T., Cardasis, H. L., Spellman, D. S., Liaw, A., Yates, N. A., & Hendrickson, R. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910776107 · Cited by 87
“2037 Da], a protein associated with coronary artery disease (25) and demonstrates a unique and potentially promising approach for studying the distribution and function of discrete protein isoforms.”
BackgroundIn search of low-frequency and rare variants affecting complex traits
Panoutsopoulou, K., Tachmazidou, I., & Zeggini, E. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt376 · Cited by 85
“R19X appears to have drifted up in frequency independently in the two population isolates (37,38).”
BackgroundDavidson, M. H. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000019 · Cited by 88
“This is of potential clinical importance, because an elevated level of Apo C-III associated with VLDL and LDL particles has been found to be an independent predictor of cardiovascular disease (CVD) event risk [32], and loss-of-function polymorphisms in the Apo C-III gene have been associated with reduced CVD event ris…”
BackgroundTriglycerides on the rise: should we swap seats on the seesaw?
Libby, P. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu500 · Cited by 85
“of an inactive APOC3 gene have lower triglycerides and lowercoronary artery calcium scores than unaffected individuals.(10) Two independent large studies recently published in New England Journal of Medicine provide strong evidence for the causal role of APOC3 and triglycerides in atherosclerotic vascular disease.”
Mital, S. R., Musunuru, K., Garg, V., Russell, M. W. W., Lanfear, D. E., Gupta, R. M., Hickey, K. T., Ackerman, M. J., Perez, M. V., Roden, D. M., et al. (2016) · Circulation Cardiovascular Genetics · doi:10.1161/hcg.0000000000000031 · Cited by 89
Highlighting Residual Atherosclerotic Cardiovascular Disease Risk
Matsuura, Y., Kanter, J. E., & Bornfeldt, K. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311999 · Cited by 94
New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
Kim, K., Ginsberg, H. N., & Choi, S. H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0198 · Cited by 80
“A genome-wide association study (GWAS) showed that heterozygous carriers of a null mutation in the APOC3 gene had lower serum TG levels and reduced subclinical atherosclerosis than noncarriers [72].”
BackgroundGenetics of Coronary Artery Disease
Musunuru, K., & Kathiresan, S. (2010) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082509-141637 · Cited by 83
Ginsberg, H. N., & Goldberg, I. J. (2023) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.122.317966 · Cited by 80
APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism
Giammanco, A., Spina, R., Cefalu, A. B., & Averna, M. R. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01080-8 · Cited by 94
Daily Stressors, Past Depression, and Metabolic Responses to High-Fat Meals: A Novel Path to Obesity
Kiecolt-Glaser, J. K., Habash, D. L., Fagundes, C. P., Andridge, R., Peng, J., Malarkey, W. B., & Belury, M. A. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.018 · Cited by 82
“The magnitude and duration of the postprandial triglyceride response are linked with the progression of atherosclerosis (41,48,49).”
BackgroundValenti, L. V. C., Nobili, V., Al‐Serri, A., Rametta, R., Leathart, J. B. S., Zappa, M. A., Dongiovanni, P., Fracanzani, A. L., Alterio, A., Roviaro, G., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.03.035 · Cited by 89
Apolipoprotein CIII links islet insulin resistance to β-cell failure in diabetes
Åvall, K., Ali, Y., Leibiger, I. B., Leibiger, B., Moede, T., Paschen, M., Dicker, A., Daré, E., Köhler, M., Ilegems, E., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1423849112 · Cited by 80
“4 insulin sensitivity and longevity, lower incidence of hypertension and protection against cardiovascular diseases (11, 12).”
BackgroundTriglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis
Zhang, B., Yin, F., Qiao, Y.-N., & Guo, S. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.909151 · Cited by 104
Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia
Bergmark, B. A., Marston, N. A., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., Kang, Y. M., Weinland, J., Murphy, S. A., Goodrich, E. L., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2507227 · Cited by 78
Absolute quantification of apolipoproteins and associated proteins on human plasma lipoproteins
von Zychlinski, A., Williams, M. J. A., McCormick, S. P. A., & Kleffmann, T. (2014) · Journal of Proteomics · doi:10.1016/j.jprot.2014.04.030 · Cited by 87
“Low apoC3 levels favor a healthier lipid profile with reduced triglyceride levels which accounts for apoC3's implication inCVD [34].”
Alvi, S. S., Ansari, I. A., Ahmad, M. K., Iqbal, J., & Khan, M. S. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.116 · Cited by 78
Qamar, A., Khetarpal, S. A., Khera, A. V., Qasim, A., Rader, D. J., & Reilly, M. P. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.305415 · Cited by 76
“One previous genotyping study of an APOC3 variant in the Lancaster Amish and 2 recent sequencing studies in large populations identified loss-of-function variants in APOC3 that were associated with lower plasma triglycerides and reduced CAD risk.(6,7,19) These 3 studies have established a direct casual genetic role fo…”
BackgroundMonocytes and macrophages as protagonists in vascular complications of diabetes
Kanter, J. E., Hsu, C.-C., & Bornfeldt, K. E. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00010 · Cited by 76
A Common Variant in the SETD7 Gene Predicts Serum Lycopene Concentrations
D’Adamo, C. R., D’Urso, A., Ryan, K. A., Yerges‐Armstrong, L. M., Semba, R. D., Steinle, N., Mitchell, B. D., Shuldiner, A. R., & McArdle, P. F. (2016) · Nutrients · doi:10.3390/nu8020082 · Cited by 82
Self-citationGeneroso, G., Janovsky, C. C. P. S., & Bittencourt, M. S. (2019) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000468 · Cited by 69
RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia
Gaudet, D., Clifton, P., Sullivan, D., Baker, J., Schwabe, C., Thackwray, S., Scott, R., Hamilton, J., Given, B., Melquist, S., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2200325 · Cited by 71
van Capelleveen, J. C., Bernelot Moens, S. J., Yang, X., Kastelein, J. J. P., Wareham, N. J., Zwinderman, A. H., Stroes, E. S. G., Witztum, J. L., Hovingh, G. K., Khaw, K.-T., et al. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.309007 · Cited by 72
Apolipoprotein C-III: Going Back to the Future for a Lipid Drug Target
Huff, M. W., & Hegele, R. A. (2013) · Circulation Research · doi:10.1161/circresaha.113.301464 · Cited by 70
Panoutsopoulou, K., Hatzikotoulas, K., Xifara, D. K., Colonna, V., Farmaki, A.-E., Ritchie, G. R. S., Southam, L., Gilly, A., Tachmazidou, I., Fatumo, S., et al. (2014) · Nature Communications · doi:10.1038/ncomms6345 · Cited by 70
Triglyceride-Rich Lipoproteins and Coronary Artery Disease Risk: New Insights From Human Genetics
Khetarpal, S. A., & Rader, D. J. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.305172 · Cited by 69
“Notably, 1 of the 4 variants studied by Crosby et al,(41) a nonsense mutation R19X (rs76353203) was previously shown in an Amish population to reduce TG and improve the clearance of dietary fat in an oral fat challenge and was associated with reduced coronary artery calcium scores, a surrogate measurement of atheroscl…”
BackgroundButler, A. A., Zhang, J., Price, C. A., Stevens, J. R., Graham, J. L., Stanhope, K. L., King, S. M., Krauss, R. M., Bremer, A. A., & Havel, P. J. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.007528 · Cited by 74
“For example, ApoC3 is positively associated with atherogenic dyslipidemia and risk of cardiovascular disease (62-64).”
BackgroundKiecolt-Glaser, J. K., Jaremka, L., Andridge, R., Peng, J., Habash, D., Fagundes, C. P., Glaser, R., Malarkey, W. B., & Belury, M. A. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.11.018 · Cited by 70
Wolska, A., Lo, L., Sviridov, D. O., Pourmousa, M., Pryor, M., Ghosh, S. S., Kakkar, R., Davidson, M., Wilson, S., Pastor, R. W., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw7905 · Cited by 70
“On the basis of both rare loss-of-function mutations (34) and common variants in large genome-wide association studies (35), apoC-III has been shown to be a major determinant of plasma TG and to be causally linked to CVD.”
BackgroundA rare variant in APOC3 is associated with plasma triglyceride and VLDL levels in Europeans
Timpson, N. J., Walter, K., Min, J. L., Tachmazidou, I., Malerba, G., Shin, S.-Y., Chen, L., Futema, M., Southam, L., Iotchkova, V., et al. (2014) · Nature Communications · doi:10.1038/ncomms5871 · Cited by 68
“%) in the general European population and does not contribute to variance in TG in this study 29,30 .”
Lipin — The bridge between hepatic glycerolipid biosynthesis and lipoprotein metabolism
Khalil, M. B., Blais, A., Figeys, D., & Yao, Z. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.07.008 · Cited by 71
“Deficiency in APOC3 in humans leads to low plasma TAG concentrations and reduced incidence of coronary artery calcification [107].”
BackgroundPlaque Calcification: Do Lipoproteins Have a Role?
Akers, E. J., Nicholls, S. J., & Bartolo, B. A. D. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.311574 · Cited by 74
Whole genome sequence analysis of blood lipid levels in >66,000 individuals
Selvaraj, M. S., Li, X., Li, Z., Pampana, A., Zhang, D. Y., Park, J., Aslibekyan, S., Bis, J. C., Brody, J. A., Cade, B. E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33510-7 · Cited by 69
Self-citationPathophysiology of hypertriglyceridemia
Hassing, H. C., Surendran, R. P., Mooij, H. L., Stroes, E. S. G., Nieuwdorp, M., & Dallinga‐Thie, G. M. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.11.010 · Cited by 85
“Indeed, low levels of apoC-III, due to a loss of function mutation, results in rapid postprandial clearance due to efficient LPL-mediated hydrolysis [30].”
BackgroundKaragiannis, G. S., Weile, J., Bader, G. D., & Minta, J. O. (2013) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-13-4 · Cited by 89
“APOC3 inhibits the catabolism and hepatic uptake of apoB-containing lipoproteins and enhances the catabolism of HDL particles, as well as the adhesion of monocytes to vascular endothelial cells and activates inflammatory signaling pathways [60].”
BackgroundHypertriglyceridemia—causes, significance, and approaches to therapy
Santos-Baez, L. S., & Ginsberg, H. N. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00616 · Cited by 66
“Importantly, the risk for cardiovascular disease (CVD) increases across the range of TG, at least until it is about 1,000 mg/dl, at which point the major risk becomes acute pancreatitis, although risk for CVD remains increased.”
BackgroundInfluentialXue, Y., Mezzavilla, M., Haber, M., McCarthy, S., Chen, Y., Narasimhan, V. M., Gilly, A., Ayub, Q., Colonna, V., Southam, L., et al. (2017) · Nature Communications · doi:10.1038/ncomms15927 · Cited by 74
Lipoproteins in chronic kidney disease: from bench to bedside
Speer, T., Ridker, P. M., von Eckardstein, A., Schunk, S. J., & Fliser, D. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa1050 · Cited by 69
Antisense Technology: An Emerging Platform for Cardiovascular Disease Therapeutics
Lee, R. G., Crosby, J., Baker, B. F., Graham, M. J., & Crooke, R. M. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9495-7 · Cited by 65
“The importance of apoC-III was highlighted in an Old World Amish population where a heterozygous loss-of-function allele for APOC3 resulted in significantly reduced plasma TG and LDL-C, as well as increased HDL-C [67].”
BackgroundInfluentialThe Genetics of Obesity and the Metabolic Syndrome
Monda, K. L., North, K. E., Hunt, S. C., Rao, D. C., Province, M. A., & Kraja, A. T. (2010) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/187153010791213100 · Cited by 79
Postprandial Plasma Phospholipids in Men Are Influenced by the Source of Dietary Fat
Meikle, P. J., Barlow, C. K., Mellett, N. A., Mundra, P. A., Bonham, M. P., Larsen, A., Cameron‐Smith, D., Sinclair, A. J., Nestel, P. J., & Wong, G. (2015) · Journal of Nutrition · doi:10.3945/jn.115.210104 · Cited by 68
“In addition, mutations in several key apolipoproteins such as the null mutation in apolipoprotein C3 (25) and gain-of-function polymorphism in the lipoprotein lipase gene (12) associate with reduced triglyceride concentrations and diminished coronary heart disease risk.”
BackgroundValleix, S., Verona, G., Jourde‐Chiche, N., Nédelec, B., Mangione, P. P., Bridoux, F., Mangé, A., Doǧan, A., Goujon, J., Lhomme, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms10353 · Cited by 68
“The lipid/protein association was expressed as percentage of the turbidity of DMPC vesicles in the absence of apoC-III; the time required to reduce the initial absorbance at 325nm by 50% was determined from the curves to compare the lipid-binding properties of the two apoC-III isoforms.”
BackgroundInfluentialExploring apolipoprotein C-III: pathophysiological and pharmacological relevance
Packard, C. J., Pirillo, A., Tsimikas, S., Ference, B. A., & Catapano, A. L. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvad177 · Cited by 61
Li, H., Han, Y., Qi, R., Wang, Y., Zhang, X., Yu, M., Tang, Y., Wang, M., Shu, Y.-N., Huang, W. Y., et al. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv192 · Cited by 67
“R19X) in the gene encoding ApoCIII tends to have a cardioprotective effect and is associated with a reduced risk of coronary heart disease.(13,43) – 46 As we saw no difference in ApoCIII2/2 mice, we do not think it is merely a sample size problem.”
BackgroundChang, M.-H., Yesupriya, A., Ned, R. M., Mueller, P. W., & Dowling, N. F. (2010) · BMC Medical Genetics · doi:10.1186/1471-2350-11-62 · Cited by 65
Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases
Geldenhuys, W. J., Lin, L., Darvesh, A. S., & Sadana, P. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.10.007 · Cited by 64
“In a GWAS published in 2008, Pollin et al. uncovered the cardioprotective effect of APOC3 in the Lancaster Amish population among carriers of the null mutation in the APOC3 gene [62].”
Nordestgaard, B. G., & Tybjærg-Hansen, A. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834477d2 · Cited by 67
Ginsberg (2011) · doi:10.1161/atvbaha.110.221846 · Cited by 64
ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets
Akoumianakis, I., Zvintzou, E., Kypreos, K. E., & Filippatos, T. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00914-7 · Cited by 70
Kolovou, G. D., Watts, G. F., Mikhailidis, D. P., Pérez-Martínez, P., Mora, S., Bilianou, H., Panotopoulos, G., Katsiki, N., Ooi, T. C., Lopez-Miranda, J., et al. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190507110519 · Cited by 61
Jian, W., Edom, R. W., Wang, D., Weng, N., & Zhang, S. (. (2013) · Analytical Chemistry · doi:10.1021/ac3034757 · Cited by 61
Using ALoFT to determine the impact of putative loss-of-function variants in protein-coding genes
Balasubramanian, S., Fu, Y., Pawashe, M., McGillivray, P., Jin, M., Liu, J., Karczewski, K. J., MacArthur, D. G., & Gerstein, M. (2017) · Nature Communications · doi:10.1038/s41467-017-00443-5 · Cited by 60
Evidence of a Polygenic Origin of Extreme High-Density Lipoprotein Cholesterol Levels
Motazacker, M. M., Peter, J., Treskes, M., Shoulders, C. C., Kuivenhoven, J. A., & Hovingh, G. K. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301505 · Cited by 61
“For example, 2 splice-site variants in APOC3 most probably gave rise to increased HDL-C in these patients as a direct consequence of enhanced lipoprotein lipase-mediated plasma triglyceride hydrolysis.(45) For other high-impact rare variants (nonsense, splice-site, and coding indel) in PCSK5, PLEC, ABCA8, C5orf35, and…”
BackgroundApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance
Ramms, B., Patel, S., Nora, C., Pessentheiner, A. R., Chang, M. W., Green, C. R., Golden, G. J., Secrest, P., Krauss, R. M., Metallo, C. M., et al. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m093740 · Cited by 59
“More importantly, it needs to be determined whether the distinctly different TG clearance pathways modulated by APOC-III have a differential impact on CVD and longevity, which are associated with altered plasma apoC-III levels in the human population.”
InfluentialMendelian Randomization: Application to Cardiovascular Disease
Timpson, N. J., Wade, K. H., & Smith, G. D. (2011) · Current Hypertension Reports · doi:10.1007/s11906-011-0242-7 · Cited by 71
“Further GWAS within an Amish population found a 48% decrease in triglycerides, a 22% increase in HDL cholesterol, and a 65% decrease in coronary artery calcification to be a direct consequence of heterozygosity for the R19X stop codon in the APOC111 gene, found in 5% of the population [57].”
BackgroundNew wrinkles in lipoprotein lipase biology
Davies, B. S. J., Beigneux, A. P., Fong, L. G., & Young, S. G. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834d0b33 · Cited by 59
“apo-CIII also has a profound impact on lipolysis; heterozygosity for an APOC3 nonsense mutation lowers plasma triglyceride levels, and a complete deficiency of apo-CIII greatly accelerates lipolysis [14,47].”
BackgroundTherapeutic RNA-silencing oligonucleotides in metabolic diseases
Goga, A., & Stoffel, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00407-5 · Cited by 58
Lowering apolipoprotein CIII delays onset of type 1 diabetes
Holmberg, R., Refai, E., Höög, A., Crooke, R. M., Graham, M., Olivecrona, G., Berggren, P.-O., & Juntti-Berggren, L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019553108 · Cited by 59
“On the contrary, about 5% of the Lancaster (PA) Amish population are heterozygous carriers of a null mutation (R19X) in the gene encoding apoCIII, and this results in a lifelong 50% reduction of the apoCIII levels and an apparent cardioprotection (13).”
BackgroundSundaram, M., Zhong, S., Khalil, M. B., Zhou, H., Jiang, Z. G., Zhao, Y., Iqbal, J., Hussain, M. M., Figeys, D., Wang, Y., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m005108 · Cited by 59
Panagiotou, O. A., Evangelou, E., & Ioannidis, J. P. A. (2010) · American Journal of Epidemiology · doi:10.1093/aje/kwq234 · Cited by 58
Intrahepatic Role of Exchangeable Apolipoproteins in Lipoprotein Assembly and Secretion
Sundaram, M., & Yao, Z. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.241455 · Cited by 57
“An APOC3-null mutation identified in Lancaster Amish population was associated with hypotriglyceridemia.(41) An intrahepatic role of human apoCIII in promoting VLDL assembly/secretion was discovered in transfection studies with human apoC-III–expressing McA-RH7777 cells cultured under lipid- rich conditions (eg, media…”
BackgroundLai, C., Wojczynski, M. K., Parnell, L. D., Hidalgo, B., Irvin, M. R., Aslibekyan, S. W., Province, M. A., Absher, D., Arnett, D. K., & Ordovás, J. M. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m069948 · Cited by 62
Allelic and phenotypic spectrum of plasma triglycerides
Johansen, C. T., & Hegele, R. A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.007 · Cited by 61
Raman fingerprints of amyloid structures
Flynn, J. D., & Lee, J. C. (2018) · Chemical Communications · doi:10.1039/c8cc03217c · Cited by 57
Akbari, P., Sosina, O. A., Bovijn, J., Landheer, K., Nielsen, J. B., Kim, M., Aykul, S., De, T., Haas, M. E., Hindy, G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32398-7 · Cited by 66
Self-citationBlattmann, P., Schuberth, C., Pepperkok, R., & Runz, H. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003338 · Cited by 56
“GWAS [1–23].”
Koska, J., Yassine, H., Trenchevska, O., Sinari, S., Schwenke, D. C., Yen, F. T., Billheimer, D., Nelson, R. W., Nedelkov, D., & Reaven, P. D. (2016) · Journal of Lipid Research · doi:10.1194/jlr.p064816 · Cited by 55
“Naturally occurring loss-of-function mutations in APOC3 are associated with decreased coronary artery calcification and a reduced risk of ischemic cardiovascular disease (18, 19).”
The RNA-binding protein vigilin regulates VLDL secretion through modulation of Apob mRNA translation
Mobin, M. B., Gerstberger, S., Teupser, D., Campana, B., Charisse, K., Heim, M. H., Manoharan, M., Tuschl, T., & Stoffel, M. (2016) · Nature Communications · doi:10.1038/ncomms12848 · Cited by 55
Rocha, N. A., East, C., Zhang, J., & McCullough, P. A. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0697-3 · Cited by 54
Kiecolt-Glaser, J. K., Fagundes, C. P., Andridge, R., Peng, J., Malarkey, W. B., Habash, D., & Belury, M. A. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.149 · Cited by 54
Target Populations for Novel Triglyceride-Lowering Therapies
Nordestgaard, A. T., Tybjærg-Hansen, A., Mansbach, H., Kersten, S., Nordestgaard, B. G., & Rosenson, R. S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.02.035 · Cited by 54
Hindy, G., Dornbos, P., Chaffin, M. D., Liu, D. J., Wang, M., Selvaraj, M. S., Zhang, D., Park, J., Aguilar-Salinas, C. A., Fulton, L., et al. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.11.021 · Cited by 83
Self-citationAn Overview of the New Frontiers in the Treatment of Atherogenic Dyslipidemias
Rached, F. H., Chapman, M. J., & Kontush, A. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.85 · Cited by 57
Metadata
- Authors
- Pollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., Mitchell, B. D., Miller, M., O'Connell, J. R., & Shuldiner, A. R.
- Affiliations
- University of Maryland, Baltimore (US)
- Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
- Corresponding author
- Pollin, Toni I.
- ORCID
- Venue
- Science
- Published
- 2008-12-12
- Volume
- 322
- Issue
- 5908
- Pages
- 1702-1705
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC2673993
- OpenAlex
- W2061100095
- Semantic Scholar
- d46146fa9f89ec4722b99bade97f6a1d685409c0
- Cited by
- 688
- References
- 34
- Citations by year
- 2026: 31 · 2025: 33 · 2024: 30 · 2023: 30 · 2022: 30 · 2021: 41 · 2020: 38 · 2019: 36 · 2018: 52 · 2017: 51 · 2016: 54 · 2015: 49 · 2014: 55 · 2013: 43 · 2012: 23
- FWCI
- 22.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (R01-AG-18728, R01AG018728)
- National Heart, Lung, and Blood Institute (U01HL72515, U01HL084756, U01HL072515, R01HL088119)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK072488)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR046838)
- National Center for Research Resources (M01RR016500, M01RR000052, M01RR 16500)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- apolipoprotein C-III, plasma lipid profile, triglycerides, HDL cholesterol, LDL cholesterol, coronary artery calcification, subclinical atherosclerosis, cardioprotection, coronary artery disease, lipolysis
- MeSH terms
- Adult, Cholesterol, Christianity, Coronary Artery Disease, Dietary Fats, Fasting, Female, Haplotypes, Heterozygote, Humans, Lipids, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Mutation, Pedigree, Pennsylvania, Risk Factors, Triglycerides, Linkage Disequilibrium, Polymorphism, Single Nucleotide, Apolipoprotein C-III, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.